Home › Entities › academia › Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age

Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age

Research article (Journal of Ophthalmology, 2018) · cited 24× · AI/ML
academia openalex:W2791750786
Press Enter · cited answer in seconds

Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age

Summary

Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age is a scholarly article[1].

Key Facts

  • Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age's instance of is recorded as scholarly article[2].

References

Programmatic citations — every numbered marker resolves to a verifiable graph row below.

Direct Wikidata claims

  1. [2] ↑ . wikidata.org.

Class ancestry

  1. [1] ↑ . Wikidata. wikidata.org.

📑 Cite this page

Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.

APA 4ort.xyz Knowledge Graph. (2026). Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age. Retrieved May 24, 2026, from https://4ort.xyz/entity/refractive-and-biometric-outcomes-in-patients-with-retinopathy-of-prematurity-treated-with-intravitreal-injection-of-ran
MLA “Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/refractive-and-biometric-outcomes-in-patients-with-retinopathy-of-prematurity-treated-with-intravitreal-injection-of-ran.
BibTeX @misc{4ortxyz_refractive-and-biometric-outcomes-in-patients-with-retinopathy-of-prematurity-treated-with-intravitreal-injection-of-ran_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age}}, year = {2026}, url = {https://4ort.xyz/entity/refractive-and-biometric-outcomes-in-patients-with-retinopathy-of-prematurity-treated-with-intravitreal-injection-of-ran}, note = {Accessed: 2026-05-24}}
LLM prompt According to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age — https://4ort.xyz/entity/refractive-and-biometric-outcomes-in-patients-with-retinopathy-of-prematurity-treated-with-intravitreal-injection-of-ran (retrieved 2026-05-24)

Canonical URL: https://4ort.xyz/entity/refractive-and-biometric-outcomes-in-patients-with-retinopathy-of-prematurity-treated-with-intravitreal-injection-of-ran · Last refreshed: